Cargando…
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II...
Autores principales: | Spampanato, Carmine, Feeney, Erin, Li, Lishu, Cardone, Monica, Lim, Jeong-A, Annunziata, Fabio, Zare, Hossein, Polishchuk, Roman, Puertollano, Rosa, Parenti, Giancarlo, Ballabio, Andrea, Raben, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662313/ https://www.ncbi.nlm.nih.gov/pubmed/23606558 http://dx.doi.org/10.1002/emmm.201202176 |
Ejemplares similares
-
AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease
por: Gatto, Francesca, et al.
Publicado: (2017) -
Atg5(flox)-Derived Autophagy-Deficient Model of Pompe Disease: Does It Tell the Whole Story?
por: Lim, Jeong-A, et al.
Publicado: (2017) -
Modulation of mTOR signaling as a strategy for the treatment of Pompe disease
por: Lim, Jeong‐A, et al.
Publicado: (2017) -
Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
por: Meena, Naresh Kumar, et al.
Publicado: (2020) -
Pompe disease: from pathophysiology to therapy and back again
por: Lim, Jeong-A, et al.
Publicado: (2014)